Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Core Viewpoint - Salarius Pharmaceuticals has regained compliance with Nasdaq's Minimum Bid Price Requirement, marking a significant step towards meeting all continued listing standards [1][2]. Compliance and Listing Status - Salarius received notification from Nasdaq on September 4, 2025, confirming compliance with Listing Rule 5550(a)(2) [1]. - The company has until October 20, 2025, to regain compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement [2]. - A Mandatory Panel Monitor will oversee Salarius for one year starting September 4, 2025, to ensure ongoing compliance [3]. Merger with Decoy Therapeutics - Salarius announced a definitive merger agreement with Decoy Therapeutics, a preclinical biopharmaceutical company, on January 13, 2025 [4]. - The merger aims to create value through Decoy's peptide conjugate therapeutics pipeline, targeting unmet medical needs in respiratory infectious diseases and GI oncology [5]. - The combined company will incorporate Salarius' oral small molecule protein degrader SP-3164 into a new drug candidate [5]. Leadership and Development Plans - The new entity will be led by Decoy's co-founders and key executives, including CEO Frederick "Rick" Pierce and Salarius' Acting CEO Mark Rosenblum [6]. - Decoy plans to advance its lead asset, a pan-coronavirus antiviral, towards an Investigational New Drug (IND) application with the FDA within the next 12 months [7]. - Salarius' seclidemstat is also undergoing a Phase 1/2 clinical study for myelodysplastic syndrome and chronic myelomonocytic leukemia [8]. Company Profiles - Salarius Pharmaceuticals focuses on developing treatments for cancer, with its lead candidate seclidemstat currently in clinical trials [10]. - Decoy Therapeutics specializes in designing peptide conjugate drug candidates using machine learning and AI, targeting serious unmet medical needs in respiratory viruses and GI cancers [9].